"Surpass(ing)" an era of basal-bolus insulin therapy: tirzepatide vs insulin lispro tid added-on to poorly controlled basal insulin-treated type 2 diabetes

被引：0
|
作者：
Frias, J. P. [1 ]
Rosenstock, J. [2 ]
Rodbard, H. W. [3 ]
Tofe, S. [4 ]
Sears, E. [5 ]
Huh, R. [5 ]
Lando, L. Fernandez [5 ]
Patel, H. [5 ]
机构：
[1] Velocity Clin Res, Los Angeles, CA USA
[2] Velocity Clin Res Med City, Dallas, TX USA
[3] Endocrine & Metab Consultants, Rockville, MD USA
[4] Univ Hosp Son Espases, Palma De Mallorca, Spain
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
6
引用
收藏
页码：S5 / S6
页数：2
相关论文
共 50 条
  • [31] Efficacy of switching from basal-bolus insulin therapy to twice-daily insulin degludec/insulin aspart co-formulation plus insulin aspart in patients with poorly controlled type 2 diabetes
    Gunes, E.
    Gunes, M.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (14) : 6691 - 6699
  • [32] Randomised open-label trial of insulin lispro protamin suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients
    Giugliano, D.
    Cleall, S.
    Pontiroli, A. E.
    Koivisto, V.
    DIABETOLOGIA, 2011, 54 : S421 - S422
  • [33] Basal-bolus insulin regimen is effective for hospitalized patients with type 2 diabetes
    不详
    Nature Clinical Practice Endocrinology & Metabolism, 2007, 3 (12): : 791 - 792
  • [34] OPTIMAL REGIMENS OF THE BASAL-BOLUS INSULIN THERAPY IN ADOLESCENTS WITH TYPE 1 DIABETES MELLITUS
    Galkina, G. A.
    Voropay, A. A.
    Levkovich, M. A.
    Vorobiov, S. V.
    Komkova, M. V.
    Morozova, N. V.
    BYULLETEN SIBIRSKOY MEDITSINY, 2015, 14 (05): : 15 - U223
  • [35] Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin
    Herz, M
    Arora, V
    Sun, B
    Ferguson, SC
    Bolli, GB
    Frier, BM
    DIABETIC MEDICINE, 2002, 19 (11) : 917 - 923
  • [36] The Effect of Type and Daily Doses of Insulin to Treatment Success in Type 2 Diabetes Patients who are Receiving Basal-bolus Insulin Therapy
    Ozturkmen, Yuksel Asli
    Avci, Suna
    Calim, Aslihan
    Cetin, Elif Guven
    Demir, Nazan
    Mazi, Emrah Erkan
    Borlu, Fatih
    Altuntas, Yuksel
    MEDICAL BULLETIN OF SISLI ETFAL HOSPITAL, 2020, 54 (04): : 416 - 423
  • [37] An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal-Bolus Insulin in Type 2 Diabetes
    Lingvay, Ildiko
    Catarig, Andrei-Mircea
    Lawson, Jack
    Chubb, Barrie
    Gorst-Rasmussen, Anders
    Evans, Lyndon Marc
    DIABETES THERAPY, 2023, 14 (01) : 123 - 137
  • [38] Tirzepatide versus insulin lispro in type 2 diabetes: SURPASS-6 trial
    Clauss, R. Maria
    DIABETOLOGIE UND STOFFWECHSEL, 2024, 19 (01) : 26 - 26
  • [39] GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis
    Castellana, Marco
    Cignarelli, Angelo
    Brescia, Francesco
    Laviola, Luigi
    Giorgino, Francesco
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35 (01)
  • [40] Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
    Yoon, Kun-Ho
    Hardy, Elise
    Han, Jenny
    DIABETES & METABOLISM JOURNAL, 2017, 41 (01) : 69 - 74
12345